Introduction
Phencyclidine (1-(1-phenylcyclohexyl)piperidine,C AS 956-90-1,PCP, I, Scheme 1) wasoriginallyintroduced as ageneralanestheticagent [1] [2] [3] .Thiscompound and its analoguess howed manybiologicalp ropertiesincluding highlypotentand widelyabused psychotomimeticpropertiesw hichaffectt he centraln ervous system [4] .They alsodisplayanalgesic, stimulating,depressiveand hallucinogeniceffects on the specificbinding sitesin brain [2] . PCP bindst oN-methyl-D-asparate( NMDA)receptor complexand blocksNMDA-mediated gating of the calciumchannel conductance [5, 6] .The analgesiceffectof ketamine (2-O-chlorophenyl-2-methylaminocyclohexan, CAS 1867-66-9,I I, Scheme 1),the otherPCP analogue, wasfirst described byDomino etal .i n1 965 [7] .Itis widelyknownasanNMDA receptorantagonist and its interactionsw itho therr eceptors arebeing increasingly recognized. Even though glutamatereceptors playessentialrolesin synaptogenesisand neuronalsurvival [8, 9] , theyalsoi nfluencecell deathi nduced byexcitotoxicity [9] [10] [11] .Ketamine isalow-affinity,use-dependent, non-competitiveantagonist of NMDA receptors [12] [13] [14] .The blockade isu se-dependentin whichthe rates of onsetand the recovery from blockade arei ncreased upon applying NMDA agonists [15] .Ketamine concentration-based differencesin the mechanismo fNMDA receptorblockade alsoh aveclinicali mplications,in whichthe analgesicpropertiesof ketamine appears at lowlevelsand the anestheticeffects appearatmuch higherconcentrations [15] .
Upton ow,manyanaloguesof phencyclidine have been synthesized [16] [17] [18] [19] [20] [21] [22] and theirpharmacologicalactivitieshavebeen investigated. Thereforeaspart of our objectivest oo btain selective,non-competitiveantagonists att he PCP binding siteo nNMDA receptorcomplex,1-[1-(3-methylphenyl) (tetralyl)]piperidine (PCP-CH 3 -tetralyl,I II, Scheme 1),wasproduced asananalogueo f I withamethylg roupo nthe aromaticring ( mposition) and aphenylg roupo nthe cyclohexane ring
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(1-(1-Phenylcyclohexyl)piperidine (PCP)I
Thiscompound wasprepared according toareported method [24] from 1-piperidinocyclohexanecarbonitrile ( IV)and phenyl magnesiumbromide. The hydrochloride saltof I wasprepared using 2-propanol and HCland wasrecrystallized from 2-propanol [24] .
2.2.21-Piperidinotetralylcarbonitrile V
1g(0.0068m ol) 1-tetralone wasadded toasolutioncontaining 0.582g( 0.0068mol) of piperidine in 0.253gHCl( 37 %) and 1.36 gcold water.Then,0.465gKCN in 1.02 ml water,50ml ethanol and 0.1 gtetra-n-buthylammoniumbromide (0.0003 mol) wereadded and the resulting mixturewass tirred atambient temperature( 25°C). The progress of the reaction wascontrolled using TLC (thin layerchromatography)( 7:3ethylace-tate/n-hexane). Afterone week,no furtherprogress wasobserved. Thus,the productw asextracted withchloroform (75ml,3h). Then,the organiclayerw ass eparated,dried and concentrated.Ano ilyr esiduewasobtained,whichwaspassed 
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2.3Pharmacologicaltests
Adultfemale Wistarr ats (Pasteur Institute,T ehran),weighing 250-300 gatt he beginning of the experimentw ererandomly selected and eachgroupofthree tof our wereh oused in acage atatemperature-controlled colonyr oom underlight/darkcycles.Animalsweregiven free access towaterand standardlaboratory ratchow(Pars Company,T ehran,I ran [18] )( I, II, III)o ran equivalentv olume of saline (control),the rats (n =7-9 in each group) werehoused in ananimalrestrainer.Then,the last 5cm of theirt ailsw asfirst submerged in room temperaturewater (22~24°C)tocheckf oranaversion towaterand afterwards wasimmersed in 52°Cwater.The reaction time between immersing the tail and its removalo ut of the heated waterw as measured.Ac ut-off latencyof 20 sw asemployed toavoid damaging the tail.
2.3.2Formalin test
The formalin test introduced byDubuisson and Dennis [28] 
Chemistry
Phencyclidine ( I )and 1-[1-(3-methylphenyl) (tetralyl) piperidine ( III)weresynthesized byr eaction of substituted Grignardreagents and carbonitrile compounds ( IV, V )( Scheme 3). Amethylg roupwass ubstituted on the aromaticring of the molecule ( III)too btain more electron distribution and dipole moment'sproperties. Common proceduresw ereapplied fort he synthesisof compounds I and IV withthe appropriatemodifications described previously [24] . Bromobenzene and its m -methyl( II)d erivativewere reacted withm agnesiumtof ormGrignardreagent, whichwast hen reacted withthe appropriatep iperidinocyclohexanecarbonitrile ( IV)and piperidinotetralylcarbonitrile ( V ). The reaction between the Grignardreagentand the carbonitrile wass lowand incomplete;t o overcome thisdeficiency,the molarratio of Grignardreagentt ocarbonitrile wasincreased [29] .
Spectroscopicdata(IR, 1 Ha nd 13 CN MR, Mass)confirmed the structureo fthe newcompounds III and V . The melting points of knowncompoundsalsoconfirmed theiridentity.The purity of eachcompound was checked byTLC using ethylacetate/n-hexane ast he eluent.
3.2Pharmacology
Generalconsideration
Mortality (numberof death),morbidity (defined asany abnormalcondition orbehaviorduetoadisorder),irritability (ac ondition of aggressiveness orincreased responseo nh andling) and otherr elated abnormalstates wereo bserved in experimentalanimals.However,c omparison of the motorcoordination index(measured by rota-rod apparatus,H arvard,U K)i ndicated no significantdifferencesbetween control and treatmentr ats.
3.2.2Analgesica ctivity of PCP (I),ketamine (II)and 1-[1-(3-methylphenyl) (tetralyl) piperidine (III) hydrochlorideswithtail immersion and formalin tests
Intraperitoneali njection of PCP ( I ),ketamine ( II)and PCP-CH 3 -tetralyl( III)h ydrochloride (6mg/kg) (dissolved in saline) generated asignificantanalgesiceffect in the tail immersion test.Comparison of the analgesic effectof thesed rugss howed amarked anti-nociception 2-25min afterketamine injection. However,thisanalgesiceffectlasted for40min following PCP-CH 3 -tetralylapplication (Fig. 1) . The dataobtained from the formalin test showed thatchronicpain could be significantlyattenuated byketamine,P CP and PCP-CH 3 -tetralyl ( Fig. 2) . The differencei nthe tail immersion latenciesand pain scoresw eree valuated using analysisof variance( ANOVA). Its eemst hats trong electron donating propertiesof the methylg roupo n meta position of the phenylring and alsoi ncorporation of ane xtraa romatica nd flat phenylg roupo nthe cyclohexane ring (ac onjugated cyclicketone,1-tetralone) ( III)increasethe binding tendencyt oNMDA receptorcomplexand tail immersion latenciesin comparison withk etamine and PCP with higherhalf-life.
Discussion
Phencyclidine (PCP)wasoriginallydeveloped asahumananesthetic, but its utilization in humanm edicine wasdiscontinued soon afterwardsbecauseofits serious psychologicalside effects [30] .Therefore,itisno more thanapharmacologicaltool interesting atleast through its derivativesoranalogues [31] .Electrophysiological and binding studieshaverevealed thatv arious antagonists of NMDA receptors,including phencyclidine,ketamine and MK-801bind toPCP-sitem ainlyw hen the channelsareinthe open oractivated state [18] .Previous studiess uggested thatketamine mayinteractw iththe NMDA receptorattwopotentiallydistinctsites:one site located within the channel poreand asecond siteassociated withthe hydrophobicdomain of the protein. The binding of the agonist tothe receptorisassumed to modifyt he binding of ketamine tobothsites [32] .Ketamine isformulated asahighlyw aters oluble hydrochloride saltbut underphysiologicalconditions,alarge fraction of the druge xists in the lipid-soluble form. Therefore,the concentration of ketamine in the lipid phasei ss everalo rders of magnitude greatert hanthat in aqueous phase [33] .Ketamine gainsaccess toa blockers iteassociated withthe lipid membrane of the lipid protein interface. Onthe otherhand,the predominanceo fclosed-channel blockade suggests thatketamine's analgesicpropertiesmightr esultfrom closedchannel rathert hano pen-channel blockade [33, 34] . Becauseo fstrongeranalgesiceffects of some of the synthesized derivativesof PCP withm ethyl,methoxy, hydroxylg roupson phenyland cyclohexane rings [17, 21] , higherelectron distribution and dipole moments of the methylg roup [16] a nd fordecreasing in conversion of conformation isomers of the drug [23] , anewderivativeo fPCP ( III)and its carbonitrile intermediatewith differents ubstitutionsin its phenyland cyclohexane ringsw eresynthesized and the analgesiceffects were studied.
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Comparison of the tail immersion and formalin tests dataindicatest hatPCP-CH 3 -tetralyld iminished thermalbut notchemical( formalin) acutep ain. Itindicates thatdifferentmechanismsarei nvolved in the thermal and chemicalacutep ain whichcausesuchd ifferentr esponses.However,the long lasting effectforPCP-CH 3 -tetralyli ncomparison withk etamine and PCP could be related tothe longerhalf-life of III.The analgesiceffect of ketamine and PCP-CH 3 -tetralyli ni nitialand late phasesof formalin chronicpain (phaseII)showed that theseanti-nociceptivee ffects occur viathe centraln ervous system (CNS). Inthisregard,chronicformalin pain (phaseII)i sr eported tobem ediated byinflammatory mediators and duetoCNS activation [35] . 
